SCHEMBL4675307

SCHEMBL4675307

O=C(C=C(O)c1nc[nH]n1)c1ccc(-c2ccccc2)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.46
ALDH1A1 P00352 3/20 0.46
SLC9A1 P19634 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
MGAM O43451 2/20 0.41
GAA P10253 2/20 0.41
SI P14410 2/20 0.41
MGAM2 Q2M2H8 2/20 0.41
PDE4B Q07343 5/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
PKM P14618 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675863 0.97 HPGD (0.50) HPGDALDH1A1SLC9A1ERCC5FEN1
SCHEMBL4674008 0.89 ALDH1A1 (0.43) HPGDALDH1A1SLC9A1MGAMGAA
SCHEMBL4673621 0.89 MGAM (0.42) HPGDALDH1A1ERCC5FEN1MGAM
SCHEMBL4672582 0.87 NR4A1 (0.55) SLC9A1MGAMGAASIMGAM2
SCHEMBL4675280 0.84 KDM4E (0.46) HPGDALDH1A1SLC9A1MGAMGAA
SCHEMBL4672776 0.82 ALDH1A1 (0.38) HPGDALDH1A1SLC9A1MEN1NPC1
SCHEMBL4676882 0.82 MAPT (0.34) HPGDALDH1A1GAAMEN1NPC1
SCHEMBL4671760 0.81 MEN1 (0.35) ALDH1A1MEN1NPC1LMNAKMT2A
SCHEMBL4678961 0.81 PTGER1 (0.36) ALDH1A1MEN1NPC1KMT2AMAPT
SCHEMBL4676006 0.81 NPSR1 (0.37) ALDH1A1SLC9A1NPC1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HPGD 2816/4885ALDH1A1 980/4885SLC9A1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.